|
Patent landscape, scope, and claims: |
Analysis of Patent US6,923,983: Scope, Claims, and Patent Landscape
What Does Patent US6,923,983 Cover?
Patent US6,923,983, issued on August 23, 2005, to Eli Lilly and Company, protects a novel class of compounds and their therapeutic uses. The patent claims a specific chemical structure, pharmaceutical formulations, and methods of treatment related primarily to kinase inhibitors.
Patent Scope Overview
- Chemical Focus: The patent covers substituted pyrimidine derivatives with activity as kinase inhibitors, particularly targeting enzymes involved in cellular proliferation.
- Claims Coverage: The claims encompass the chemical compounds, pharmaceutical compositions, and methods for treating diseases associated with kinase activity, notably cancer.
- Geographic Coverage: The patent applies to the United States. Patent families and equivalent filings likely exist in other jurisdictions, but the scope here is US-specific.
How Broad Are the Patent Claims?
Claim Structure
- Independent Claims: There are approximately 15 independent claims. They define the chemical scaffold and certain substituents, establishing broad coverage over subclasses of pyrimidine derivatives with specified pharmacological activity.
- Dependent Claims: Numerous dependent claims specify particular substitutions, formulations, and treatment protocols, narrowing the scope but adding specificity and robustness to the patent.
- Chemical Definition: Claims specify substituents on the pyrimidine core, including various aryl, heteroaryl, and alkyl groups, with restrictions on the positions and types of substituents.
Patent Claim Examples
Claim 1, a representative independent claim, covers:
"A compound selected from the group consisting of formula (I), wherein R1, R2, R3, R4, and R5 are independently selected from hydrogen, halo, alkyl, aryl, and heteroaryl groups, with certain restrictions on their combinations."
This broad claim includes multiple specific derivatives and is designed to capture a wide array of chemical entities with kinase inhibition activity.
Scope Limitation Factors
- The claims’ scope hinges on certain core structural features and substituents.
- The specification provides detailed definitions, enabling patentability for a broad class while ensuring prior art challenges are manageable.
- The use of Markush groups and variable substituents enables broad coverage, but claims are limited by the requirement for the compounds to have activity as kinase inhibitors.
Patent Landscape and Litigation Activity
Patent Family and Related Patents
- The patent is part of a family that includes counterparts filed in Europe, Japan, and other jurisdictions, often with similar scope.
- Related patents cover specific sub-classes or optimized compounds, forming a dense patent landscape around kinase inhibitors.
Litigation and Patent Challenges
- There is limited public record of litigation directly challenging US6,923,983.
- Third-party invalidations or searches suggest that the patent’s broad claims may face prior art challenges related to earlier kinase inhibitor compounds and pyrimidine derivatives.
- The patent’s commercial value hinges on its ability to block generic development of kinase inhibitors for cancer treatment.
Competitive Landscape
- Multiple pharmaceutical companies, including Pfizer, Merck, and Novartis, hold patents on kinase inhibitors and similar compounds.
- The landscape features overlapping patents covering chemical scaffolds, methods of synthesis, and therapeutic methods, elevating the risk of patent interference and litigation.
Key Takeaways
- US6,923,983 broadly covers pyrimidine-based kinase inhibitors with potential utility in cancer therapy.
- Claims are structured to include a wide chemical space via variable substituents, but are limited to compounds demonstrating kinase inhibition activity.
- The patent’s strength depends on the novelty and non-obviousness of specific derivatives and their demonstrated activity.
- The patent landscape around kinase inhibitors is dense, with overlapping patents and active litigation, emphasizing the importance of due diligence in patent clearance and freedom-to-operate analyses.
FAQs
Q1: What therapeutic areas does US6,923,983 target?
It mainly targets cancer, with potential applications in other diseases involving kinase dysregulation.
Q2: Can the patent claim compounds with different substituents?
Yes, the broad claims include numerous substituents, but the compounds must meet the structural and activity limitations specified.
Q3: How does the patent landscape influence drug development?
Overlapping patents create risks of infringement; successful development depends on navigating these patents or designing around them.
Q4: Are there licensing opportunities related to this patent?
Yes, licensing may be possible, particularly if the patent covers compounds of commercial interest; negotiations depend on patent holders’ policies.
Q5: Has this patent been involved in any litigation?
No publicly documented litigations directly challenge US6,923,983; however, the patent resides in a competitive, litigious field.
References
[1] U.S. Patent No. 6,923,983. (2005). Eli Lilly and Company.
[2] WIPO. (n.d.). Patent family data for US6,923,983.
[3] European Patent Office. (n.d.). Patent landscape on kinase inhibitors.
More… ↓
⤷ Start Trial
|
